In an effort to explain the underlying mechanism, we have revealed that aberrant TIGAR expression inhibits glycolysis but activates the glutamine pathway, which may facilitate ESCC cell survival and progression. The gene discussed is TIGAR; the disease is esophageal squamous cell carcinoma.